References

1. PCL-K1005-001-11. LEO Pharma - Data on file.
2. In vitro release test. LEO Pharma - Data on file.
3. Kleresca® Acne Treatment Instructions for Use.
4. Nikolis, A. et al. An estension of a multicentre, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. Int J Dermatol 2017 (In press). 
5. Endothelial cell study. LEO Pharma - Data on file.
6. Kleresca® Skin Rejuvenation Instructions for Use.
7. Antoniou, C. et al. (2016), A multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. Int J Dermatol 2016; 55: 1321 - 1328.
8. SKR1. LEO Pharma - Data on file.
9. SKR Safety Report. LEO Pharma - Data on file.
10. Skin insert study. LEO Pharma - Data on file.
11. Cho, S.B., et al., Non-ablative 1550-nm erbium-glass and ablative 10 600-nm carbon dioxide fractional lasers for acne scars: a randomized split-face study with blinded response evaluation. J Eur Acad Dermatol Venereol, 2010; 24(8): 921-5.
12. KL-K1005-P001. LEO Pharma - Data on file.
13. Ozolins, M., et al., Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet, 2004; 364(9452): 2188-95.
14. Thielitz, A. and H. Gollnick, Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol, 2008; 9(6): 369-81.
15. Hamilton, F.L., et al., Laser and other light therapies for the treatment of acne vulgaris: systematic review. Br J Dermatol, 2009; 160(6): 1273-85.
16. Sakamoto, F.H.; et al. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part I. Acne vulgaris: when and why consider photodynamic therapy? J Am Acad Dermatol, 2010; 63(2): 183-93; quiz 193-4.
17. James, W.D., Clinical practice. Acne. N Engl J Med, 2005; 352(14): 1463-72.
18. McManus, P. and I. Iheanacho, Don't use minocycline as first line oral antibiotic in acne. BMJ, 2007; 334(7585): 154.
19. Limited, R.P. Roaccutane 10mg Soft Capsules summary of product characteristics. 2012  11 August 2015]; Available from: http://www.medicines.org.uk/emc/medicine/1727.
20. Zheng, W., et al. Evidence-based review of photodynamic therapy in the treatment of acne. Eur J Dermatol, 2014; 24(4): 444-56.
21. Nikolis, A., et al. A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation. Clin. Cosmet. Investig. Dermatol, 2016; 9: 115 – 125.
22. Nielsen, M. E., et al. Introducing: photobiomodulation by low energy chromophore-induced fluorescent light. Mechanisms of Photobiomodulation Therapy. In IV, SPIE Photonics West BIOS, San Francisco 28 January – 2 February 2017.
23. Kwon, H. H. et al. The clinical and histological effect of home-use, combination blue-red LED phototherapy for mild-to-moderate acne vulgaris in Korean patients: a double-blind, randomized controlled trial. Br. J. Dermatol, 2013; 168: 1088–94.
24. Gold, M. H. et al. Clinical efficacy of home-use blue-light therapy for mild-to moderate acne. J. Cosmet. Laser Ther. 2011; 13: 308–14. 
25. Ash, C., et al. A randomized controlled study for the treatment of acne vulgaris using high-intensity 414 nm solid state diode arrays. J. Cosmet. Laser Ther. 2015;17(4):170-6
26. DUSA Pharmaceuticals Inc. DUSA Pharmaceuticals reports results from Phase II clinical trial for PDT of moderate to severe acne. (2006). at http://www.marketwired.com/press-release/DUSA-Pharmaceuticals-Reports-Results-from-Phase-II-Clinical-Trial-PDT-Moderate-Severe-578172.htm
27. Hession, M. T. & Graber, E. M. Atrophic acne scarring: a review of treatment options. J. Clin. Aesthet. Dermatol, 2015; 8: 50–8.
28. Freitas, L.F. de & Hamblin, M.R. Proposed Mechanisms of photobiomodulation or low level light therapy. 2016; EEE J Sel Top Quantum Electron 22.